QUICK ANSWER
- How will Medicare price negotiation affect Botox billing in urology? Medicare drug price negotiation is a federal program that sets a maximum fair price for selected high-cost drugs, and Botox is one of the first physician-administered drugs selected. As of November 2026, the negotiated price for Botox takes effect January 1, 2028, which changes how urology practices are paid for onabotulinumtoxinA, billed as J0585, when injected into the bladder under CPT 52287.
- What changed: CMS issued its Medicare Drug Price Negotiation Program final rule, CMS-4215-F, on November 5, 2026.
- Why urology cares: Botox is one of four primarily Part B drugs in the 2028 cycle, and urology bills it for overactive bladder.
- What is still pending: CMS has said final guidance on how Part B practices receive the negotiated price in 2028 is coming in fall 2026.
What CMS Finalized on November 5
On November 5, 2026, CMS issued the Medicare Drug Price Negotiation Program final rule, CMS-4215-F, published in the Federal Register on November 9 and effective December 5, 2026. The rule codifies the Negotiation Program for initial price applicability year 2029 and beyond, after CMS ran the first three cycles through program guidance. CMS has published a fact sheet summarizing the final rule.
For urology, the rule matters because of what happens in 2028. On January 27, 2026, CMS selected 15 drugs for the third negotiation cycle, the first cycle to include drugs paid under Medicare Part B. Botox is one of four drugs on that list with most of its Medicare spending under Part B, along with Cimzia, Entyvio, and Orencia, according to analyses by Health Affairs and Avalere. CMS’s negotiation period for this cycle ended on November 1, 2026, and the negotiated prices take effect January 1, 2028.
The final rule also sets the program’s direction. Starting with the 2029 cycle, CMS will select up to 20 drugs covered under Part D or payable under Part B each year. The rule adds a new policy targeting manufacturers that try to avoid selection by launching new formulations of the same drug, and it codifies how CMS publishes and explains negotiated prices.
Most important for buy-and-bill practices, CMS said it intends to release final guidance in fall 2026 on how the maximum fair price will be effectuated in 2028, including for drugs payable under Part B. CMS plans to codify effectuation rules for 2029 and later through rulemaking in 2027.
As of November 2026, CMS has not yet published the negotiated price for Botox.
Which Urology Practices Are Affected?
Urology practices that inject onabotulinumtoxinA into the bladder for overactive bladder or neurogenic detrusor overactivity are affected, because they buy the drug, bill J0585 under Medicare Part B, and are paid based on the drug’s price. Practices that refer these patients elsewhere, or treat them only with oral medication or neuromodulation, are not directly affected.
One question we hear constantly from urology practice managers is whether a federal drug pricing program can touch the practice at all. For Botox, it can, because urology is one of the specialties that buys the drug, stores it, injects it, and bills Medicare for both the procedure and the drug.
- Office-based urology practices. Practices that perform bladder Botox injections in the office bill CPT 52287 for the cystourethroscopy with injection and J0585 for the drug units. Drug payment is the part that changes.
- Hospital-based and ASC urologists. When the procedure happens in a hospital outpatient department, the facility typically bills the drug, so the effect lands on the facility rather than the urologist’s professional claim.
- Practices with heavy overactive bladder volume. Groups that built a third-line overactive bladder program around Botox have the most drug spend at stake. Accurate diagnosis coding, such as ICD-10 code N32.81 for overactive bladder, remains the foundation for every claim.
- Groups planning growth or acquisitions. Practices reviewing their payer mix and drug margins, a trend we covered in our post on independent urology practice consolidation, should factor 2028 drug pricing into their projections, since buy-and-bill drug margin is part of what drives practice valuation.
Why Part B Drugs Were Added to Negotiation
The Inflation Reduction Act of 2022 created the Negotiation Program and phased it in. The first two cycles covered only Part D drugs, which patients fill at pharmacies. Starting with the 2028 cycle, the law added Part B drugs, which physicians buy and administer in the office or hospital.
That shift brings price negotiation into the buy-and-bill model for the first time. Under Part B, separately payable physician-administered drugs are typically paid at average sales price plus 6%, with the 6% intended to help cover the cost of acquiring, storing, and handling the drug. According to Milliman’s analysis of Part B negotiation dynamics, a lower negotiated price also shrinks that add-on, because the add-on is calculated on a lower base.
In our experience matching urology groups with billing partners, drug reimbursement is one of the least understood parts of practice revenue. Many practices know their procedure payments well but have never modeled what happens to drug margin when the underlying price drops, even though drug payments can rival procedure payments.
The 2028 cycle is also only the beginning. The final rule raises the annual selection limit to up to 20 drugs starting with 2029, and analysts have noted that more high-spending Part B drugs are likely to be selected in later cycles. Urology practices that use other physician-administered drugs, such as hormone therapies for prostate cancer, should watch future selection lists closely.
Prior authorization pressure on Botox is a separate issue, covered in our post on the WISeR model and urology prior authorization.
What Could the Negotiated Price Mean in Dollars?
If Medicare pays Part B drugs with a negotiated price at 106% of that price, as the statute provides, a lower negotiated price reduces both the drug payment and the 6% add-on. Milliman illustrates this with a drug at a $1,000 average sales price and a $400 negotiated price, where the add-on falls from $60 to $24.
| Payment element | Before negotiation (illustration) | With negotiated price (illustration) |
| Drug price basis | $1,000 average sales price | $400 maximum fair price |
| 6% add-on | $60 | $24 |
| Total Medicare payment | $1,060 | $424 |
| Effective date | Current Part B payment | January 1, 2028, for selected drugs |
These numbers are an illustration of the mechanics, not Botox’s actual prices. CMS had not published Botox’s negotiated price as of November 2026, and the effectuation guidance for Part B is still pending.
The practical question is what happens to the practice’s cost. If manufacturers ensure practices can acquire Botox at or near the negotiated price, the practice’s margin per unit may shrink mainly because the 6% add-on is smaller. If acquisition cost does not fall to match Medicare payment, a practice could be paid less than it spends on the drug. Milliman also notes potential pressure on commercial reimbursement once a negotiated Medicare price exists.
That is why practices should model their own Botox volume, units per injection, current acquisition cost, and payer mix before 2028, rather than relying on national averages. A practice injecting a small number of patients may see little change, while a high-volume program could see a meaningful shift in drug revenue across Medicare patients alone.
What Should Urology Practices Do Now?
There is no billing change for Botox in 2027, but the preparation work starts now, because the data practices need for 2028 decisions comes from claims they are billing today. These steps help practices get ready:
- Measure your Botox volume. Pull a year of CPT 52287 and J0585 claims by payer, including units billed per injection.
- Document acquisition cost. Record what the practice pays per unit today, including any discounts or rebates.
- Watch for the negotiated price. Check CMS’s Negotiation Program page for the published Botox price and effectuation guidance.
- Model 2028 margin. Compare projected Medicare payment against acquisition cost to see whether the drug remains viable in your setting.
- Review commercial contracts. Check whether any payer contracts reference Medicare drug payment rates.
- Tighten documentation. Keep conservative therapy history, diagnosis, and units clearly documented for every injection.
- Track wastage rules. Continue reporting discarded units correctly so drug claims stay clean under current Part B rules and audits.
Providers often come to us after realizing their drug revenue has been leaking for years through unit errors and missed documentation. Billing companies in our network that specialize in urology track drug claims at the unit level, which is exactly the data practices will need to model 2028 and to decide whether in-office Botox still makes sense.
Billing bladder Botox and want a clear view of your drug revenue before 2028? Get matched with urology billing companies that handle buy-and-bill drug billing, free, usually within 30 minutes.
Common Misreadings of Botox Negotiation
The most common issue we see providers run into is assuming a drug pricing program only affects pharmacies and patients. For Part B drugs, it reaches the practice’s own revenue. These misreadings come up often.
- “The new price starts in 2027.” Negotiated prices for the 2028 cycle, including Botox, take effect January 1, 2028. Nothing changes in Botox payment because of negotiation in 2027.
- “The final rule set Botox’s price.” The November 5 rule codifies the program for 2029 and later. The Botox price comes from the 2028 negotiation cycle and is published separately.
- “The procedure payment changes too.” Negotiation applies to the drug. CPT 52287 is paid under the Physician Fee Schedule, which has its own 2027 changes, such as those we covered in our post on G2211 deletion in 2027.
- “Hospital Botox prior authorization now covers bladder injections.” In the CY 2027 hospital outpatient final rule, CMS added eight botulinum toxin codes to its prior authorization program starting July 1, 2027, and stated that the bladder injection procedure is not among them.
- “Commercial payers are unaffected.” Commercial contracts are separate, but analysts expect negotiated Medicare prices to influence commercial reimbursement over time.
- “Medicare Advantage is excluded.” CMS counts Medicare Advantage spending on Part B drugs when it ranks drugs for selection, so heavy Medicare Advantage use of a drug still counts toward its selection.
- “Unit errors do not matter.” As drug payment tightens, every incorrectly billed unit costs more. Clean unit reporting is the easiest margin to protect, and our post on Q4 2026 NCCI urology edits covers related edits.
In-House Billing vs. a Urology Billing Partner
Most urology practices bill drugs in-house alongside their procedures, often with the same staff who handle cystoscopy, biopsy, and stone claims. That works when the drug list is short and payment is stable. Botox negotiation changes the picture because the practice will need unit-level data, acquisition cost tracking, and payer-by-payer modeling to decide whether in-office Botox remains financially viable after 2028.
In-house teams often track procedure denials closely but treat drug lines as an afterthought. Missed units, incorrect wastage reporting, and unbilled drug lines are common sources of lost revenue, and they become more expensive as drug margins narrow. Practices that have never run a drug margin report will struggle to make the 2028 decision with confidence. The same data also supports contract negotiations, prior authorization appeals, and the coding reviews that keep drug claims paying the first time.
Urology Bill Co, part of Billing Service Quotes, matches urology practices with billing companies in our network that handle urology procedures and buy-and-bill drug billing. We have matched more than 2,000 providers across all 50 states, the service is free to providers, and most practices are connected within 30 minutes. Our process includes a human review of each request, so a practice with a Botox program is matched with billing companies that understand drug billing.
Billing companies in our network offer credentialing, contracting, compliance, and full revenue cycle support, and many are software agnostic. Rates start as low as 2.95%. For a refresher on core cystoscopy coding, see our CPT 52000 billing guide.
Frequently Asked Questions
Is Botox selected for Medicare drug price negotiation?
Yes. CMS selected Botox on January 27, 2026, as one of 15 drugs in the third negotiation cycle, the first to include Part B drugs. Botox is one of four selected drugs with most of its Medicare spending under Part B. Its negotiated price takes effect January 1, 2028.
When does the negotiated Botox price take effect?
Negotiated prices for the third cycle, including Botox, take effect January 1, 2028. CMS’s negotiation period for this cycle ended November 1, 2026. As of November 2026, CMS had not yet published the negotiated price for Botox or its final Part B effectuation guidance.
How will Medicare pay for Botox after negotiation?
Under the Inflation Reduction Act, Part B payment for a selected drug during its price applicability period is based on the negotiated maximum fair price plus 6%, rather than average sales price plus 6%. A lower base also reduces the 6% add-on. CMS guidance will detail how practices receive the price.
Does the negotiation change CPT 52287 payment?
No. Negotiation applies to the drug, billed as J0585 for onabotulinumtoxinA. CPT 52287, cystourethroscopy with bladder injection, is paid under the Physician Fee Schedule and is not changed by the Negotiation Program, though fee schedule updates still apply each year.
What did the November 5, 2026 final rule change?
The final rule, CMS-4215-F, codifies the Negotiation Program for 2029 and later, allows CMS to select up to 20 drugs a year starting in 2029, and addresses new formulations used to avoid selection. It takes effect December 5, 2026. Part B effectuation guidance for 2028 is expected separately.
Does hospital outpatient prior authorization apply to bladder Botox?
In the CY 2027 hospital outpatient final rule, CMS added eight botulinum toxin injection codes to its prior authorization program starting July 1, 2027, and stated that the bladder injection procedure is not among them. Commercial and Medicare Advantage plans may still require authorization.
Next Steps
- Coding overactive bladder? Review our ICD-10 code N32.81 guide.
- Tracking 2027 hospital changes? Read about urology OPPS billing changes for 2027.
- Billing bladder procedures? See our CPT 52204 bladder biopsy guide.
- Ready for help? Explore Urology Bill Co and get matched with a billing partner.
CPT codes and descriptors are maintained by the American Medical Association, and HCPCS Level II codes are maintained by CMS. Both are provided here for reference. The payment figures in the table are an illustration of the pricing mechanics drawn from third-party analysis, not Botox’s actual prices; CMS had not published the negotiated price for Botox as of November 2026, and Part B effectuation guidance was still pending. Negotiation Program policies, selected drug lists, prior authorization requirements, and payment rules change over time, so verify against CMS’s published guidance and your Medicare Administrative Contractor before relying on any figure here for budgeting or billing.
Get your Botox and drug billing ready for 2028. Get matched with urology billing companies that handle buy-and-bill drugs, free, with rates as low as 2.95%.